Martin Markowitz
Overview
Explore the profile of Martin Markowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
7390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vabret N, Najburg V, Solovyov A, Gopal R, McClain C, Sulc P, et al.
iScience
. 2022 Jul;
25(7):104599.
PMID: 35789859
Pattern recognition receptors (PRRs) protect against microbial invasion by detecting specific molecular patterns found in pathogens and initiating an immune response. Although microbial-derived PRR ligands have been extensively characterized, the...
2.
St Bernard L, Abolade J, Mohri H, Markowitz M, Evering T
J Virol
. 2020 Aug;
94(20).
PMID: 32759323
HIV-1 evolution in the cerebrospinal fluid (CSF) and plasma may result in discordant drug resistance mutations (DRMs) in the compartments. Single-genome amplification (SGA) was used to generate partial HIV-1 polymerase...
3.
4.
Markowitz M, Grobler J
Curr Opin HIV AIDS
. 2019 Oct;
15(1):27-32.
PMID: 31658118
Purpose Of Review: To discuss the potential role of islatravir (ISL), a novel reverse transcriptase translocation inhibitor, in the treatment and prevention of human immunodeficiency virus type 1 (HIV-1) infection....
5.
Markowitz M, Gettie A, St Bernard L, Andrews C, Mohri H, Horowitz A, et al.
J Infect Dis
. 2019 Jun;
221(9):1398-1406.
PMID: 31175822
Background: MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine [EFdA]) is a novel reverse transcriptase-translocation inhibitor. Methods: We assessed MK-8591 as preexposure prophylaxis in the rhesus macaque model of intrarectal challenge with simian/human immunodeficiency virus (SHIV)....
6.
Saxena M, Sabado R, La Mar M, Mohri H, Salazar A, Dong H, et al.
Front Immunol
. 2019 Apr;
10:725.
PMID: 31024557
Toll-like receptor-3 agonist Poly-ICLC has been known to activate immune cells and induce HIV replication in pre-clinical experiments. In this study we investigated if Poly-ICLC could be used for disrupting...
7.
Murray M, Markowitz M, Frank I, Grant R, Mayer K, Hudson K, et al.
HIV Clin Trials
. 2018 Nov;
19(4):129-138.
PMID: 30445896
Background: Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre-exposure prophylaxis (PrEP). Objective: We report participant outcomes from the...
8.
Zhang L, Peng P, Wu Y, Ma X, Soe N, Huang X, et al.
AIDS Behav
. 2018 Jul;
23(2):523-533.
PMID: 29971734
Risk of HIV infection is high in Chinese MSM, with an annual HIV incidence ranging from 3.41 to 13.7/100 person-years. Tenofovir-based PrEP is effective in preventing HIV transmission in MSM....
9.
Markowitz M, Sarafianos S
Curr Opin HIV AIDS
. 2018 Apr;
13(4):294-299.
PMID: 29697468
Purpose Of Review: 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a nucleoside reverse transcriptase inhibitor (NRTI) with a novel mechanism of action, unique structure, and amongst NRTIs, unparalleled anti-HIV-1 activity. We will summarize its...
10.
McPherson T, Sobieszczyk M, Markowitz M
Expert Opin Investig Drugs
. 2018 Apr;
27(4):413-420.
PMID: 29633869
Human Immunodeficiency Virus (HIV) is a chronic infection that depletes the immune system of essential components causing those infected to be at risk for multiple life-threatening infections. Worldwide, millions live...